Adaptimmune

FDA signs off on Adaptimmune's Tecelra as the first engineered cell therapy for a solid tumor
Fierce Pharma
Fri, 08/2/24 - 11:32 am
Adaptimmune
FDA
Tecelra
afami-cel
synovial sarcoma
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Adaptimmune
afami-cel
advanced synovial sarcoma
Lykos Therapeutics
MDMA
PTSD
Bristol Myers Squibb
KarXT
schizophrenia
Daiichi Sankyo
AstraZeneca
Dato-DXd
non-small cell lung cancer
Galapagos selects Adaptimmune T-cell therapy for $665M biobucks collab
Fierce Biotech
Fri, 05/31/24 - 10:52 am
Galapagos
Adaptimmune
biobucks
t-cell therapies
uza-cel
ovarian cancer
5 Cell and Gene Therapy Decisions to Watch in 2024
BioSpace
Mon, 04/22/24 - 11:38 am
cell therapy
gene therapy
Pfizer
Beqvez
hemophilia B
Abeona Therapeutics
pz-cel
recessive dystrophic epidermolysis bullosa
Rocket Pharmaceuticals
Kresladi
Leukocyte adhesion deficiency-1
Adaptimmune
afami-cel
advanced synovial sarcoma
Autolus Therapeutics
obe-cel
B cell acute lymphoblastic leukemia
Roche, Adaptimmune part ways on cell therapy research
BioPharma Dive
Sun, 04/14/24 - 01:26 pm
Roche
Genentech
cell therapy
cancer
Adaptimmune
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
Fri, 09/9/22 - 11:03 am
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy
Endpoints
Thu, 11/11/21 - 11:37 pm
Adaptimmune
ASCO 2021
TCR therapeutics
ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas
Fierce Biotech
Wed, 05/19/21 - 11:22 pm
Adaptimmune
ASCO 2021
sarcomas
soft tissue sarcomas
clinical trials
Second-quarter catalysts for the smaller players
EP Vantage
Wed, 04/7/21 - 10:25 am
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
Asco 2020 movers – cell therapy companies dominate the risers
EP Vantage
Thu, 06/4/20 - 10:56 am
ASCO 2020
cell therapy
Adaptimmune
Allogene
Iovance
Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential
MedCity News
Tue, 06/2/20 - 10:20 am
Adaptimmune
ASCO 2020
cell therapy
sarcoma
ADP-A2M4
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
BioSpace
Tue, 01/14/20 - 10:46 am
Adaptimmune
SPEAR-T
Astellas
CAR-T
cell therapy
drug development
Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency
Endpoints
Tue, 12/3/19 - 10:18 am
Adaptimmune
FDA
regenerative medicine
RMAT
ADP-A2M4
Q&A: Adaptimmune’s Elliot Norry on cell therapy
Pharmaforum
Mon, 10/14/19 - 09:28 am
cell therapy
cancer
Adaptimmune
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 04/28/19 - 10:00 pm
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Adaptimmune reports zero responses across three T cell therapy trials
BioCentury
Mon, 10/22/18 - 11:17 pm
Adaptimmune
t-cell therapies
clinical trials
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
CP Wire
Wed, 08/15/18 - 09:52 am
Adaptimmune
MAGE-A4
solid tumors
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
Wed, 08/15/18 - 09:50 am
Adaptimmune
MAGE-A4
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
CP Wire
Tue, 07/24/18 - 10:54 am
Adaptimmune
GSK
GSK3377794
T-cells
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
Tue, 07/24/18 - 10:17 am
Adaptimmune
GSK
GSK3377794

Pages